Α-synuclein misfolding and Parkinson's disease.

Substantial evidence links α-synuclein, a small highly conserved presynaptic protein with unknown function, to both familial and sporadic Parkinson's disease (PD). α-Synuclein has been identified as the major component of Lewy bodies and Lewy neurites, the characteristic proteinaceous deposits that are the hallmarks of PD. α-Synuclein is a typical intrinsically disordered protein, but can adopt a number of different conformational states depending on conditions and cofactors. These include the helical membrane-bound form, a partially-folded state that is a key intermediate in aggregation and fibrillation, various oligomeric species, and fibrillar and amorphous aggregates. The molecular basis of PD appears to be tightly coupled to the aggregation of α-synuclein and the factors that affect its conformation. This review examines the different aggregation states of α-synuclein, the molecular mechanism of its aggregation, and the influence of environmental and genetic factors on this process.

[1]  Min Zhu,et al.  The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. , 2004, The Journal of biological chemistry.

[2]  V. Uversky,et al.  Methionine oxidation inhibits fibrillation of human α‐synuclein in vitro , 2002 .

[3]  E. Richfield,et al.  Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice , 2011, Neuroscience.

[4]  D. Allsop,et al.  Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. , 2002, Free radical biology & medicine.

[5]  K. Chung,et al.  Induction of Neuronal Cell Death by Rab5A-dependent Endocytosis of α-Synuclein* , 2001, The Journal of Biological Chemistry.

[6]  V. Uversky,et al.  Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. , 2010, Biochimica et biophysica acta.

[7]  V. Buchman,et al.  Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.

[8]  D. Raleigh,et al.  A critical assessment of the role of helical intermediates in amyloid formation by natively unfolded proteins and polypeptides. , 2009, Protein engineering, design & selection : PEDS.

[9]  B. Ghetti,et al.  Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function* , 2003, Journal of Biological Chemistry.

[10]  D. A. Monte The role of environmental agents in Parkinson's disease , 2001, Clinical Neuroscience Research.

[11]  Adam Douglass,et al.  Mechanism of Prion Propagation: Amyloid Growth Occurs by Monomer Addition , 2004, PLoS biology.

[12]  Karen A. Lewis,et al.  A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. , 2005, The Journal of biological chemistry.

[13]  R. Perrin,et al.  Interaction of Human α-Synuclein and Parkinson's Disease Variants with Phospholipids , 2000, The Journal of Biological Chemistry.

[14]  M. Feany,et al.  Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. , 2005, Nature neuroscience.

[15]  B. Hyman,et al.  Heat‐shock protein 70 modulates toxic extracellular α‐synuclein oligomers and rescues trans‐synaptic toxicity , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  J. Dordick,et al.  Resveratrol Selectively Remodels Soluble Oligomers and Fibrils of Amyloid Aβ into Off-pathway Conformers* , 2010, The Journal of Biological Chemistry.

[17]  H. Lashuel,et al.  Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease. , 2009, The Journal of biological chemistry.

[18]  B. Hyman,et al.  Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. , 2010, Biochemical and biophysical research communications.

[19]  J. Winderickx,et al.  Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson. , 2008, Biochimica et biophysica acta.

[20]  M. Kataoka,et al.  X-ray solution scattering studies of protein folding. , 1996, Folding & design.

[21]  V. Uversky,et al.  Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. , 2001, Biochemistry.

[22]  I. Ziv,et al.  Mutant and wild-type α-synuclein interact with mitochondrial cytochrome C oxidase , 2002, Journal of Molecular Neuroscience.

[23]  Vladimir N. Uversky,et al.  Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation , 2007 .

[24]  R. Bradshaw,et al.  Protein translocation and turnover in eukaryotic cells. , 1989, Trends in biochemical sciences.

[25]  M. Zigmond,et al.  A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.

[26]  B. E. Staveley,et al.  parkin counteracts symptoms in a Drosophila model of Parkinson's disease , 2004, BMC Neuroscience.

[27]  A. Kanthasamy,et al.  Wild-type α-synuclein interacts with pro-apoptotic proteins PKCδ and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death , 2005 .

[28]  V. Uversky,et al.  Nuclear localization of alpha-synuclein and its interaction with histones. , 2003, Biochemistry.

[29]  Y. Sung,et al.  alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. , 2002, The Journal of biological chemistry.

[30]  A. Minton,et al.  The Influence of Macromolecular Crowding and Macromolecular Confinement on Biochemical Reactions in Physiological Media* , 2001, The Journal of Biological Chemistry.

[31]  S. Paik,et al.  Copper ( II )-induced self-oligomerization of α-synuclein , 1999 .

[32]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[33]  R. Lerner,et al.  Small molecule oxidation products trigger disease-associated protein misfolding. , 2006, Accounts of chemical research.

[34]  P. Walsh Baicalin is a Major Component of PC-SPES Which Inhibits the Proliferation of Human Cancer Cells Via Apoptosis and Cell Cycle Arrest , 2002 .

[35]  S. Lindquist,et al.  Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. , 2008, The Journal of clinical investigation.

[36]  D. Ehrnhoefer,et al.  EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers , 2008, Nature Structural &Molecular Biology.

[37]  V. Uversky,et al.  Anion-induced folding of Staphylococcal nuclease: characterization of multiple equilibrium partially folded intermediates. , 1998, Journal of molecular biology.

[38]  B. Diwan,et al.  Potential role of alpha-synuclein and metallothionein in lead-induced inclusion body formation. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[39]  Dirar Homouz,et al.  Structure, function, and folding of phosphoglycerate kinase are strongly perturbed by macromolecular crowding , 2010, Proceedings of the National Academy of Sciences.

[40]  Rodrigo Morales,et al.  Molecular Cross Talk between Misfolded Proteins in Animal Models of Alzheimer's and Prion Diseases , 2010, The Journal of Neuroscience.

[41]  M. E. Clark,et al.  Living with water stress: evolution of osmolyte systems. , 1982, Science.

[42]  M. Brin,et al.  TorsinA accumulation in Lewy bodies in sporadic Parkinson’s disease , 2000, Brain Research.

[43]  H. Erdjument-Bromage,et al.  Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. , 2003, The Journal of biological chemistry.

[44]  R. Szargel,et al.  Monoubiquitylation of α-Synuclein by Seven in Absentia Homolog (SIAH) Promotes Its Aggregation in Dopaminergic Cells* , 2008, Journal of Biological Chemistry.

[45]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Dordick,et al.  Aromatic Small Molecules Remodel Toxic Soluble Oligomers of Amyloid β through Three Independent Pathways* , 2010, The Journal of Biological Chemistry.

[47]  F. Checler,et al.  Wild-type but Not Parkinson's Disease-related Ala-53 → Thr Mutant α-Synuclein Protects Neuronal Cells from Apoptotic Stimuli* , 2000, The Journal of Biological Chemistry.

[48]  L. Serpell,et al.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Jensen,et al.  Pathogenic effects of alpha-synuclein aggregation. , 2005, Brain research. Molecular brain research.

[50]  A. Minton Implications of macromolecular crowding for protein assembly. , 2000, Current opinion in structural biology.

[51]  P. Lansbury Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Kazuyuki Takata,et al.  Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4‐phenylbutyrate, a chemical chaperone , 2007, Journal of neurochemistry.

[53]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[54]  H. Lashuel,et al.  E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. , 2009, Journal of molecular biology.

[55]  V. Uversky,et al.  Characterization of the non-fibrillar α-synuclein oligomers. , 2011, Protein and peptide letters.

[56]  Sachiko Takahama,et al.  Magnesium deficiency over generations in rats with special references to the pathogenesis of the parkinsonism–dementia complex and amyotrophic lateral sclerosis of Guam , 2006, Neuropathology : official journal of the Japanese Society of Neuropathology.

[57]  Nutan Sharma,et al.  TorsinA and heat shock proteins act as molecular chaperones: suppression of α‐synuclein aggregation , 2002, Journal of neurochemistry.

[58]  Vladimir N Uversky,et al.  Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins , 2007, Proceedings of the National Academy of Sciences.

[59]  S. Radford,et al.  A generic mechanism of beta2-microglobulin amyloid assembly at neutral pH involving a specific proline switch. , 2009, Journal of molecular biology.

[60]  Min Zhu,et al.  Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. , 2006, Biochemistry.

[61]  Jennifer C. Lee,et al.  Effect of dioxygen on copper(II) binding to alpha-synuclein. , 2010, Journal of inorganic biochemistry.

[62]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[63]  V. Uversky,et al.  Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. , 2002, FEBS letters.

[64]  V. Uversky,et al.  Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. , 2001, The Journal of biological chemistry.

[65]  J. Ridet,et al.  alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[66]  C. Masters,et al.  The structure of dopamine induced α-synuclein oligomers , 2010, European Biophysics Journal.

[67]  Gerald F. Tremblay Neuropathology , 1989, Neurology.

[68]  M. Goedert Parkinson's disease and other alpha-synucleinopathies. , 2001, Clinical chemistry and laboratory medicine.

[69]  Gregory G. Brown,et al.  Occupational exposures to metals as risk factors for Parkinson's disease , 1997, Neurology.

[70]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[71]  M. Citron,et al.  alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. , 1999, The Journal of biological chemistry.

[72]  A. Fink,et al.  Acid-induced folding of proteins. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[74]  Zheng Rong Yang,et al.  RONN: the bio-basis function neural network technique applied to the detection of natively disordered regions in proteins , 2005, Bioinform..

[75]  C. Glabe,et al.  Structural Classification of Toxic Amyloid Oligomers* , 2008, Journal of Biological Chemistry.

[76]  C. Ross,et al.  Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[77]  G C COTZIAS,et al.  Manganese in health and disease. , 1958, Physiological reviews.

[78]  E. Lattman Small angle scattering studies of protein folding , 1994 .

[79]  Songsong Cao,et al.  Torsin-Mediated Protection from Cellular Stress in the Dopaminergic Neurons of Caenorhabditis elegans , 2005, The Journal of Neuroscience.

[80]  J. Kenney,et al.  Microtubule-associated Protein 1B Is a Component of Cortical Lewy Bodies and Binds α-Synuclein Filaments* , 2000, The Journal of Biological Chemistry.

[81]  Ralf Langen,et al.  Structure of membrane-bound α-synuclein from site-directed spin labeling and computational refinement , 2008, Proceedings of the National Academy of Sciences.

[82]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[83]  David Eisenberg,et al.  Atomic structures of amyloid cross-beta spines reveal varied steric zippers. , 2007, Nature.

[84]  R. He,et al.  Ribosylation Rapidly Induces α-Synuclein to Form Highly Cytotoxic Molten Globules of Advanced Glycation End Products , 2010, PloS one.

[85]  Ad Bax,et al.  Structure and Dynamics of Micelle-bound Human α-Synuclein* , 2005, Journal of Biological Chemistry.

[86]  M. Bennett The role of α-synuclein in neurodegenerative diseases , 2005 .

[87]  Daphne H. E. W. Huberts,et al.  Macromolecular Crowding Compacts Unfolded Apoflavodoxin and Causes Severe Aggregation of the Off-pathway Intermediate during Apoflavodoxin Folding* , 2008, Journal of Biological Chemistry.

[88]  C. Ross,et al.  α-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells , 2005, The Journal of Neuroscience.

[89]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[90]  Elizabeth Head,et al.  Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers , 2007, Molecular Neurodegeneration.

[91]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[92]  S. Dudek,et al.  Transglutaminase Catalyzes the Formation of Sodium Dodecyl Sulfate‐Insoluble, Alz‐50‐Reactive Polymers of τ , 1993, Journal of neurochemistry.

[93]  P. Radivojac,et al.  PROTEINS: Structure, Function, and Bioinformatics Suppl 7:176–182 (2005) Exploiting Heterogeneous Sequence Properties Improves Prediction of Protein Disorder , 2022 .

[94]  H. Fukuyama,et al.  Dietary intake of metals and risk of Parkinson's disease: A case-control study in Japan , 2011, Journal of the Neurological Sciences.

[95]  G. Sancesario,et al.  Metal changes in CSF and peripheral compartments of parkinsonian patients , 2006, Journal of the Neurological Sciences.

[96]  H. Erdjument-Bromage,et al.  Parkinson's Disease-associated α-Synuclein Is a Calmodulin Substrate* , 2003, The Journal of Biological Chemistry.

[97]  M. Bennett The role of alpha-synuclein in neurodegenerative diseases. , 2005, Pharmacology & therapeutics.

[98]  Marco Brucale,et al.  Conformational equilibria in monomeric alpha-synuclein at the single molecule level , 2007, 0712.1973.

[99]  Seung-Jae Lee,et al.  Membrane-bound α-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form* , 2002, The Journal of Biological Chemistry.

[100]  T. Iwatsubo,et al.  Small Molecule Inhibitors of α-Synuclein Filament Assembly† , 2006 .

[101]  Vladimir N. Uversky,et al.  Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration , 2004, Cell and Tissue Research.

[102]  J R Ghilardi,et al.  Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. , 2000, Biochemistry.

[103]  R. Jakes,et al.  Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's disease , 1998, FEBS letters.

[104]  V. Uversky,et al.  The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. , 2002, The Journal of biological chemistry.

[105]  H. Band,et al.  Tau interacts with src-family non-receptor tyrosine kinases. , 1998, Journal of cell science.

[106]  F. Nikolajeff,et al.  The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers. , 2009, Biochemical and biophysical research communications.

[107]  Seho Kim,et al.  Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation. , 2008, Journal of molecular biology.

[108]  M. Dallas,et al.  α‐Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH‐SY5Y) cells , 2009, Journal of neurochemistry.

[109]  P. S. St George-Hyslop,et al.  alpha-Synuclein membrane interactions and lipid specificity. , 2000, The Journal of biological chemistry.

[110]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[111]  Jochen Klucken,et al.  Hsp70 Reduces α-Synuclein Aggregation and Toxicity* , 2004, Journal of Biological Chemistry.

[112]  Gideon Schreiber,et al.  Common crowding agents have only a small effect on protein-protein interactions. , 2009, Biophysical journal.

[113]  C. C. Johnson,et al.  Parkinson's disease mortality and the industrial use of heavy metals in Michigan , 1993, Movement disorders : official journal of the Movement Disorder Society.

[114]  C. Tanner,et al.  Environmental factors and Parkinson's disease , 1989, Neurology.

[115]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[116]  J. Rochet,et al.  α-Synuclein-induced tubule formation in lipid bilayers. , 2011, The journal of physical chemistry. B.

[117]  John Q. Trojanowski,et al.  Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.

[118]  T. Chase,et al.  Tissue transglutaminase catalyzes the formation of alpha‐synuclein crosslinks in Parkinson's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[119]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[120]  V. Subramaniam,et al.  NMR of α‐synuclein–polyamine complexes elucidates the mechanism and kinetics of induced aggregation , 2004, The EMBO journal.

[121]  Jian-Dong Huang,et al.  Baicalein Inhibits Formation of α‐Synuclein Oligomers within Living Cells and Prevents Aβ Peptide Fibrillation and Oligomerisation , 2011, Chembiochem : a European journal of chemical biology.

[122]  S. Lindquist,et al.  α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity , 2009, Nature Genetics.

[123]  Gang Xiao,et al.  Membrane-mediated Amyloidogenesis and the Promotion of Oxidative Lipid Damage by Amyloid β Proteins* , 2007, Journal of Biological Chemistry.

[124]  N. Voelcker,et al.  Annular alpha-synuclein species from purified multiple system atrophy inclusions. , 2004, Journal of neurochemistry.

[125]  L. Golbe The genetics of Parkinson's disease: A reconsideration , 1990, Neurology.

[126]  V. Subramaniam,et al.  Tissue transglutaminase modulates α‐synuclein oligomerization , 2008, Protein science : a publication of the Protein Society.

[127]  L. Petrucelli,et al.  α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins , 1999, The Journal of Neuroscience.

[128]  R. Nussbaum,et al.  Lipid Droplet Binding and Oligomerization Properties of the Parkinson's Disease Protein α-Synuclein* , 2002, The Journal of Biological Chemistry.

[129]  M. Raftery,et al.  αB-Crystallin is a major component of glial cytoplasmic inclusions in multiple system atrophy , 2009, Neurotoxicity Research.

[130]  D. Housman,et al.  New Directions for Neurodegenerative Disease Therapy: Using Chemical Compounds to Boost the Formation of Mutant Protein Inclusions , 2006, Cell cycle.

[131]  B. Giasson,et al.  Effects of Oxidative and Nitrative Challenges on α-Synuclein Fibrillogenesis Involve Distinct Mechanisms of Protein Modifications* , 2003, Journal of Biological Chemistry.

[132]  A. Steven,et al.  Membrane Curvature Induction and Tubulation Are Common Features of Synucleins and Apolipoproteins* , 2010, The Journal of Biological Chemistry.

[133]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[134]  C. Soto Prion hypothesis: the end of the controversy? , 2011, Trends in biochemical sciences.

[135]  J. Trojanowski,et al.  Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. , 2003, The American journal of pathology.

[136]  John S Lazo,et al.  Improved low molecular weight Myc-Max inhibitors , 2007, Molecular Cancer Therapeutics.

[137]  V. Uversky,et al.  Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. , 2008, Journal of molecular biology.

[138]  B. Devreese,et al.  Transglutaminase-mediated Intramolecular Cross-linking of Membrane-bound α-Synuclein Promotes Amyloid Formation in Lewy Bodies* , 2009, The Journal of Biological Chemistry.

[139]  C. Ross,et al.  Single Particle Characterization of Iron-induced Pore-forming α-Synuclein Oligomers* , 2008, Journal of Biological Chemistry.

[140]  A. Ševčovičová,et al.  Phosphorylation , 2013, Cell cycle.

[141]  V. Uversky,et al.  Agrin binds α-synuclein and modulates α-synuclein fibrillation , 2005 .

[142]  M. Kataoka,et al.  Chain-like conformation of heat-denatured ribonuclease A and cytochrome c as evidenced by solution X-ray scattering. , 1998, Folding & design.

[143]  Daniel Sage,et al.  Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. , 2008, Human molecular genetics.

[144]  A. Roses,et al.  The human NACP/alpha-synuclein gene: chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis. , 1995, Genomics.

[145]  R. Swerdlow,et al.  Microtubule Depolymerization Potentiates Alpha-Synuclein Oligomerization , 2009, Front. Ag. Neurosci..

[146]  P. Lansbury,et al.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. , 2003, Biochemistry.

[147]  C. Griesinger,et al.  Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation. , 2008, Journal of the American Chemical Society.

[148]  Daniel Otzen,et al.  p25α Stimulates α-Synuclein Aggregation and Is Co-localized with Aggregated α-Synuclein in α-Synucleinopathies* , 2005, Journal of Biological Chemistry.

[149]  P. Lansbury,et al.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.

[150]  John Q. Trojanowski,et al.  Ubiquitination of α-Synuclein Is Not Required for Formation of Pathological Inclusions in α-Synucleinopathies , 2003 .

[151]  K. Chung,et al.  Multiple ligand interaction of α-synuclein produced various forms of protein aggregates in the presence of Aβ25-35, copper, and eosin , 2001, Brain Research.

[152]  G. Campanella,et al.  [Parkinson disease and environmental factors]. , 1990, Revue d'épidémiologie et de santé publique.

[153]  Ji An Wu,et al.  Anti-HIV activity of medicinal herbs: usage and potential development. , 2001, The American journal of Chinese medicine.

[154]  Ariele Viacava Follis,et al.  Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. , 2009, Journal of the American Chemical Society.

[155]  Soo-Youl Kim,et al.  Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[156]  Vladimir N Uversky,et al.  Oncogenic Partnerships: EWS-FLI1 Protein Interactions Initiate Key Pathways of Ewing's Sarcoma , 2010, Clinical Cancer Research.

[157]  Patrick R Hof,et al.  Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brain , 2001, Brain Research.

[158]  A. Üren,et al.  A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma , 2009 .

[159]  Todd B. Sherer,et al.  Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.

[160]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[161]  R. Bucala,et al.  Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. , 1992, Advances in pharmacology.

[162]  A. Manning-Boğ,et al.  Environmental factors in Parkinson's disease. , 2002, Neurotoxicology.

[163]  C. Tanner,et al.  Rotenone, Paraquat, and Parkinson’s Disease , 2011, Environmental health perspectives.

[164]  P J McLean,et al.  Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. , 2000, The Journal of biological chemistry.

[165]  F. Kamp,et al.  Binding of α-Synuclein Affects the Lipid Packing in Bilayers of Small Vesicles* , 2006, Journal of Biological Chemistry.

[166]  Rotenone , 1932, Science.

[167]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[168]  Adam J. Trexler,et al.  Allostery in a disordered protein: oxidative modifications to α-synuclein act distally to regulate membrane binding. , 2011, Journal of the American Chemical Society.

[169]  S. Paik,et al.  Structural changes in α‐synuclein affect its chaperone‐like activity in vitro , 2000, Protein science : a publication of the Protein Society.

[170]  L. Forsgren,et al.  Dietary intake and olfactory function in patients with newly diagnosed Parkinson's disease: a case-control study , 2011, Nutritional neuroscience.

[171]  T. Iwatsubo,et al.  P4-261 Small molecule inhibitors of alpha-synuclein filament assembly , 2006, Alzheimer's & Dementia.

[172]  V. Subramaniam,et al.  Dependence of α-synuclein aggregate morphology on solution conditions , 2002 .

[173]  Xiaohui Xu,et al.  Nitrated α-Synuclein Induces the Loss of Dopaminergic Neurons in the Substantia Nigra of Rats , 2010, PloS one.

[174]  Hong-Yu Hu,et al.  Interaction with synphilin‐1 promotes inclusion formation of α‐synuclein: mechanistic insights and pathological implication , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[175]  M. Bleecker Parkinsonism: a clinical marker of exposure to neurotoxins. , 1988, Neurotoxicology and teratology.

[176]  J. Trojanowski,et al.  Parkinson's Disease and Related α‐Synucleinopathies Are Brain Amyloidoses , 2003, Annals of the New York Academy of Sciences.

[177]  J. Trojanowski,et al.  Induction of alpha-synuclein aggregation by intracellular nitrative insult. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[178]  S. Becker,et al.  Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[179]  B. Giasson,et al.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.

[180]  P. Riederer,et al.  Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.

[181]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[182]  Tetsuya Takahashi,et al.  Activation of Pyk2/RAFTK induces tyrosine phosphorylation of α‐synuclein via Src‐family kinases , 2002 .

[183]  Feng Gai,et al.  Effect of dehydration on the aggregation kinetics of two amyloid peptides. , 2009, The journal of physical chemistry. B.

[184]  Philip J. Thomas,et al.  A Precipitating Role for Truncated α-Synuclein and the Proteasome in α-Synuclein Aggregation , 2005, Journal of Biological Chemistry.

[185]  Jeff Kuret,et al.  Rapid Anionic Micelle-mediated α-Synuclein Fibrillization in Vitro* , 2003, Journal of Biological Chemistry.

[186]  Vladimir N Uversky,et al.  A Protein-Chameleon: Conformational Plasticity of α-Synuclein, a Disordered Protein Involved in Neurodegenerative Disorders , 2003, Journal of biomolecular structure & dynamics.

[187]  J. R. Menezes,et al.  Synphilin-1 Is Developmentally Localized to Synaptic Terminals, and Its Association with Synaptic Vesicles Is Modulated by α-Synuclein* , 2002, The Journal of Biological Chemistry.

[188]  Jennifer C. Lee,et al.  Evidence for copper-dioxygen reactivity during alpha-synuclein fibril formation. , 2010, Journal of the American Chemical Society.

[189]  T. Hastings,et al.  Alpha‐synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells , 2006, Journal of neurochemistry.

[190]  P. Auluck,et al.  Pharmacological prevention of Parkinson disease in Drosophila , 2002, Nature Medicine.

[191]  David Eisenberg,et al.  An amyloid-forming segment of beta2-microglobulin suggests a molecular model for the fibril. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[192]  R. Lucchini,et al.  From Manganism to Manganese-Induced Parkinsonism: A Conceptual Model Based on the Evolution of Exposure , 2009, NeuroMolecular Medicine.

[193]  H. Vorum,et al.  Ca2+ Binding to α-Synuclein Regulates Ligand Binding and Oligomerization* , 2001, The Journal of Biological Chemistry.

[194]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[195]  Bharathi,et al.  Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study. , 2007, Neuroscience letters.

[196]  J. Trojanowski,et al.  Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells , 2009, Proceedings of the National Academy of Sciences.

[197]  Henning Stahlberg,et al.  The fold of α-synuclein fibrils , 2008, Proceedings of the National Academy of Sciences.

[198]  Bernardino Ghetti,et al.  Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human α-Synuclein(1–120): Implications for Lewy Body Disorders , 2006, The Journal of Neuroscience.

[199]  C. Ross,et al.  Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease , 2001, Nature Medicine.

[200]  P. Fraser,et al.  Small Ubiquitin-like Modifier (SUMO) Modification of Natively Unfolded Proteins Tau and α-Synuclein* , 2006, Journal of Biological Chemistry.

[201]  Jennifer Stine Elam,et al.  Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS , 2003, Nature Structural Biology.

[202]  P. Lansbury,et al.  Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. , 2000, Biochemistry.

[203]  David R. Brown Metal binding to alpha-synuclein peptides and its contribution to toxicity. , 2009, Biochemical and biophysical research communications.

[204]  A. Fink The aggregation and fibrillation of alpha-synuclein. , 2006, Accounts of chemical research.

[205]  Armin Giese,et al.  Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding , 2007, The Journal of Neuroscience.

[206]  T. Ly,et al.  Protein-metal interactions of calmodulin and α-synuclein monitored by selective noncovalent adduct protein probing mass spectrometry , 2008, Journal of the American Society for Mass Spectrometry.

[207]  N. Voelcker,et al.  Annular α‐synuclein species from purified multiple system atrophy inclusions , 2004 .

[208]  William C. Nolan,et al.  Curcumin inhibits aggregation of α-synuclein , 2008, Acta Neuropathologica.

[209]  G. Petsko,et al.  The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. , 2006, Journal of molecular biology.

[210]  J. Payton,et al.  Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. , 2001, Brain research. Molecular brain research.

[211]  R. Kayed,et al.  Permeabilization of Lipid Bilayers Is a Common Conformation-dependent Activity of Soluble Amyloid Oligomers in Protein Misfolding Diseases* , 2004, Journal of Biological Chemistry.

[212]  M. Ekberg,et al.  The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional properties. , 2011, Free radical biology & medicine.

[213]  Martin Blackledge,et al.  Amino acid bulkiness defines the local conformations and dynamics of natively unfolded alpha-synuclein and tau. , 2007, Journal of the American Chemical Society.

[214]  Y. Amemiya,et al.  Protein globularization during folding. A study by synchrotron small-angle X-ray scattering. , 1996, Journal of Molecular Biology.

[215]  P. Højrup,et al.  α-Synuclein Binds to Tau and Stimulates the Protein Kinase A-catalyzed Tau Phosphorylation of Serine Residues 262 and 356* , 1999, The Journal of Biological Chemistry.

[216]  Kiowa S. Bower,et al.  Accelerated α‐synuclein fibrillation in crowded milieu , 2002 .

[217]  C. Masters,et al.  Cu2+ binding modes of recombinant alpha-synuclein--insights from EPR spectroscopy. , 2008, Journal of the American Chemical Society.

[218]  C. Griesinger,et al.  Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[219]  Jie Li,et al.  The Association of α-Synuclein with Membranes Affects Bilayer Structure, Stability, and Fibril Formation* , 2003, Journal of Biological Chemistry.

[220]  Harry B Gray,et al.  Alpha-synuclein tertiary contact dynamics. , 2007, The journal of physical chemistry. B.

[221]  K. Takata,et al.  Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice. , 2011, Biological & pharmaceutical bulletin.

[222]  V. Subramaniam,et al.  Dependence of alpha-synuclein aggregate morphology on solution conditions. , 2002, Journal of molecular biology.

[223]  Paul H. Axelsen,et al.  The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation* , 2005, Journal of Biological Chemistry.

[224]  R. Ellis Macromolecular crowding : obvious but underappreciated , 2022 .

[225]  P. S. St George-Hyslop,et al.  α-Synuclein Membrane Interactions and Lipid Specificity* , 2000, The Journal of Biological Chemistry.

[226]  L. Breydo,et al.  Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. , 2007, Biochemistry.

[227]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[228]  I. Ziv,et al.  Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. , 2002, Journal of molecular neuroscience : MN.

[229]  S. Metallo,et al.  Intrinsically disordered proteins are potential drug targets. , 2010, Current opinion in chemical biology.

[230]  A. Levey,et al.  Functional Interaction between Monoamine Plasma Membrane Transporters and the Synaptic PDZ Domain–Containing Protein PICK1 , 2001, Neuron.

[231]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[232]  V. Uversky,et al.  Pesticides directly accelerate the rate of α‐synuclein fibril formation: a possible factor in Parkinson's disease , 2001, FEBS letters.

[233]  Vladimir N Uversky,et al.  Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. , 2002, Neurotoxicology.

[234]  M. Davies,et al.  The oxidative environment and protein damage. , 2005, Biochimica et biophysica acta.

[235]  H. Kato,et al.  Calcium-triggered membrane interaction of the alpha-synuclein acidic tail. , 2006, Biochemistry.

[236]  G J Pielak,et al.  Solvent-induced collapse of alpha-synuclein and acid-denatured cytochrome c. , 2001, Protein science : a publication of the Protein Society.

[237]  D. Eliezer,et al.  Residual structure, backbone dynamics, and interactions within the synuclein family. , 2007, Journal of molecular biology.

[238]  J. Hicks,et al.  The Transition Metals , 1971 .

[239]  Heather T. McFarlane,et al.  Atomic structures of amyloid cross-β spines reveal varied steric zippers , 2007, Nature.

[240]  M Yasui,et al.  Calcium, magnesium and aluminum concentrations in Parkinson's disease. , 1992, Neurotoxicology.

[241]  O. Hornykiewicz,et al.  α-Synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter , 2004, Neuroscience Letters.

[242]  M. Frasier,et al.  Magnesium Inhibits Spontaneous and Iron-induced Aggregation of α-Synuclein* , 2002, The Journal of Biological Chemistry.

[243]  B. Hyman,et al.  Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. , 2004, The Journal of biological chemistry.

[244]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[245]  B. Hyman,et al.  Interaction of α‐synuclein and synphilin‐1: effect of Parkinson's disease‐associated mutations , 2001 .

[246]  E. Altschuler,et al.  Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. , 1999, Medical hypotheses.

[247]  A. Zoleo,et al.  Structural characterization of a high affinity mononuclear site in the copper(II)-α-synuclein complex. , 2010, Journal of the American Chemical Society.

[248]  P. Fraser,et al.  α‐Synuclein–synaptosomal membrane interactions , 2004 .

[249]  D. Bushinsky,et al.  Calcium , 1998, The Lancet.

[250]  M. Citron,et al.  Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.

[251]  A. Goldberg,et al.  PAN, the proteasome-activating nucleotidase from archaebacteria, is a protein-unfolding molecular chaperone , 2000, Nature Cell Biology.

[252]  Sun-Young Lee,et al.  α‐Synuclein exhibits competitive interaction between calmodulin and synthetic membranes , 2002, Journal of neurochemistry.

[253]  L. Serpell,et al.  Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. , 2004, FEBS letters.

[254]  V. Uversky,et al.  Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. , 2004, Chemistry & biology.

[255]  P. Worley,et al.  Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. , 1999, Nature genetics.

[256]  Jeff Kuret,et al.  Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. , 2003, The Journal of biological chemistry.

[257]  R. Perrin,et al.  Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. , 2000, The Journal of biological chemistry.

[258]  V. Uversky,et al.  The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice , 2002, The Journal of Biological Chemistry.

[259]  V. Subramaniam,et al.  Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease. , 2010, Current protein & peptide science.

[260]  H. Lashuel,et al.  Stable α-Synuclein Oligomers Strongly Inhibit Chaperone Activity of the Hsp70 System by Weak Interactions with J-domain Co-chaperones* , 2010, The Journal of Biological Chemistry.

[261]  Gabriele Meloni,et al.  Redox activity of α-synuclein-Cu is silenced by Zn₇-metallothionein-3. , 2011, Free radical biology & medicine.

[262]  David Eisenberg,et al.  Recent atomic models of amyloid fibril structure. , 2006, Current opinion in structural biology.

[263]  Sebastian Doniach,et al.  Biophysical Properties of the Synucleins and Their Propensities to Fibrillate , 2002, The Journal of Biological Chemistry.

[264]  F. Kamp,et al.  Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles. , 2006, The Journal of biological chemistry.

[265]  R. Perrin,et al.  Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins* , 2001, The Journal of Biological Chemistry.

[266]  J. Langston,et al.  Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat , 2002, Neurobiology of Disease.

[267]  C. Griesinger,et al.  Exploring the structural details of Cu(I) binding to α-synuclein by NMR spectroscopy. , 2011, Journal of the American Chemical Society.

[268]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[269]  P Choi,et al.  alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. , 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[270]  C. Dobson,et al.  Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. , 2010, Journal of molecular biology.

[271]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[272]  L. Meijer,et al.  Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. , 2000, The Journal of biological chemistry.

[273]  Daniel Harries,et al.  Crowding Alone Cannot Account for Cosolute Effect on Amyloid Aggregation , 2011, PloS one.

[274]  S Doniach,et al.  Changes in biomolecular conformation seen by small angle X-ray scattering. , 2001, Chemical reviews.

[275]  V. Uversky,et al.  Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. , 2005, Glycobiology.

[276]  Guifang Wang,et al.  19F NMR studies of alpha-synuclein conformation and fibrillation. , 2009, Biochemistry.

[277]  J. Trojanowski,et al.  Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. , 2002, Neuron.

[278]  A. Fink The Aggregation and Fibrillation of α-Synuclein , 2006 .

[279]  Pico Caroni,et al.  Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.

[280]  Patrick S Daugherty,et al.  Evolutionary optimization of fluorescent proteins for intracellular FRET , 2005, Nature Biotechnology.

[281]  Chi V. Dang,et al.  c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.

[282]  B. Hyman,et al.  Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. , 2006, Biochemical and biophysical research communications.

[283]  T. Iwatsubo,et al.  Ubiquitination of alpha-synuclein. , 2005, Biochemistry.

[284]  J. Kelly,et al.  The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. , 2007, Biochemistry.

[285]  D. Ehrnhoefer,et al.  EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity , 2010, Proceedings of the National Academy of Sciences.

[286]  Fred H. Gage,et al.  In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.

[287]  Birgit Schilling,et al.  Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. , 2009, Analytical chemistry.

[288]  V. Uversky,et al.  Certain Metals Trigger Fibrillation of Methionine-oxidized α-Synuclein* , 2003, Journal of Biological Chemistry.

[289]  T. Iwatsubo,et al.  Ubiquitination of α-Synuclein† , 2005 .

[290]  Ralf Langen,et al.  A combinatorial NMR and EPR approach for evaluating the structural ensemble of partially folded proteins. , 2010, Journal of the American Chemical Society.

[291]  E. Israeli,et al.  β‐Synuclein occurs in vivo in lipid‐associated oligomers and forms hetero‐oligomers with α‐synuclein , 2009, Journal of neurochemistry.

[292]  A. Young,et al.  Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[293]  Paul R. Carey,et al.  Secondary Structure of α-Synuclein Oligomers: Characterization by Raman and Atomic Force Microscopy , 2006 .

[294]  E. Masliah,et al.  beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. , 2001, Neuron.

[295]  V. Uversky Intrinsically Disordered Proteins , 2014 .

[296]  M. Zigmond,et al.  Erratum: "A role for α-synuclein in the regulation of dopamine biosynthesis" The Journal of Neuroscience (April 15, 2002) (3090-3099)) , 2002 .

[297]  V. Uversky,et al.  Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? , 2009, Biochimica et biophysica acta.

[298]  Mark A. Wilson,et al.  The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein , 2006 .

[299]  A. Matouschek,et al.  Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function* , 2003, The Journal of Biological Chemistry.

[300]  Ji-Eun Suk,et al.  Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers , 2011, Experimental & Molecular Medicine.

[301]  Jennifer C. Lee,et al.  Identification of the minimal copper(II)-binding alpha-synuclein sequence. , 2009, Inorganic chemistry.

[302]  Zhengguo Zhou,et al.  Crowded Cell-like Environment Accelerates the Nucleation Step of Amyloidogenic Protein Misfolding* , 2009, The Journal of Biological Chemistry.

[303]  I. Kanazawa,et al.  α-Synuclein Affects the MAPK Pathway and Accelerates Cell Death* , 2001, The Journal of Biological Chemistry.

[304]  L. Stefanis,et al.  α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells , 2005, Journal of Cell Science.

[305]  V. Uversky,et al.  Nitration inhibits fibrillation of human α‐synuclein in vitro by formation of soluble oligomers , 2003 .

[306]  M. Yoshimoto,et al.  NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[307]  P. Højrup,et al.  &agr;-Synuclein filaments bind the transcriptional regulator HMGB-1 , 2004, Neuroreport.

[308]  Donato A Di Monte,et al.  The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.

[309]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[310]  H. Ischiropoulos,et al.  Biological selectivity and functional aspects of protein tyrosine nitration. , 2003, Biochemical and biophysical research communications.

[311]  M. Sierks,et al.  Curcumin reduces α-synuclein induced cytotoxicity in Parkinson's disease cell model , 2010, BMC Neuroscience.

[312]  J. Trojanowski,et al.  Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. , 2003, Biochemistry.

[313]  J. Rochet,et al.  Adsorption of alpha-synuclein on lipid bilayers: modulating the structure and stability of protein assemblies. , 2010, The journal of physical chemistry. B.

[314]  R. Kayed,et al.  Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.

[315]  S. Shaikh,et al.  Advanced glycation end products induce in vitro cross‐linking of α‐synuclein and accelerate the process of intracellular inclusion body formation , 2008, Journal of neuroscience research.

[316]  S. Zimmerman,et al.  Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli. , 1991, Journal of molecular biology.

[317]  D. Sulzer,et al.  Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.

[318]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[319]  B. Hyman,et al.  Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. , 2009, The Journal of clinical investigation.

[320]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[321]  V. Uversky,et al.  Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation. , 2004, Biochemistry.

[322]  K. Rao,et al.  Role of advanced glycation on aggregation and DNA binding properties of α-synuclein. , 2011, Journal of Alzheimer's disease : JAD.

[323]  A. Singleton,et al.  Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. , 2004, Brain : a journal of neurology.

[324]  N. Maiti,et al.  Secondary structure of alpha-synuclein oligomers: characterization by raman and atomic force microscopy. , 2006, Journal of molecular biology.

[325]  A. Fink,et al.  Conformational states of beta-lactamase: molten-globule states at acidic and alkaline pH with high salt. , 1989, Biochemistry.

[326]  Jing Zhang,et al.  Identification of Novel Proteins Associated with Both α-Synuclein and DJ-1*S , 2007, Molecular & Cellular Proteomics.

[327]  G. Anantharamaiah,et al.  The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. , 1992, Journal of lipid research.

[328]  K. Arima,et al.  Tubulin Seeds α-Synuclein Fibril Formation* , 2002, The Journal of Biological Chemistry.

[329]  D. Allsop,et al.  Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. , 2002 .

[330]  J. Gorell,et al.  Occupational Metal Exposures and the Risk of Parkinson’s Disease , 1999, Neuroepidemiology.

[331]  B. Wolozin,et al.  Book Review: Iron and Parkinson’s Disease , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[332]  A. Doig,et al.  A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. , 2006, Biochemistry.

[333]  P. Jensen,et al.  Pathogenic effects of α-synuclein aggregation , 2005 .

[334]  C. Olanow,et al.  Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study , 1994, Brain Research.

[335]  P. Lansbury,et al.  Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? , 2002, Biochemistry.

[336]  D. Raleigh,et al.  A role for helical intermediates in amyloid formation by natively unfolded polypeptides? , 2009, Physical biology.

[337]  C. Tanner,et al.  The role of environmental toxins in the etiology of Parkinson's disease , 1989, Trends in Neurosciences.

[338]  Dmitri I Svergun,et al.  Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation , 2011, Proceedings of the National Academy of Sciences.

[339]  Vladimir N Uversky,et al.  Intrinsically disordered proteins from A to Z. , 2011, The international journal of biochemistry & cell biology.

[340]  V. Uversky,et al.  Metalloproteomics and metal toxicology of α-synuclein. , 2010, Metallomics : integrated biometal science.

[341]  J. Winderickx,et al.  Yeast unfolds the road map toward α-synuclein-induced cell death , 2010, Cell Death and Differentiation.

[342]  A. Barbeau,et al.  Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias). , 1984, Neurotoxicology.

[343]  Shubo Han,et al.  The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils* , 2004, Journal of Biological Chemistry.

[344]  D. Eliezer,et al.  Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of α-Synuclein* , 2001, The Journal of Biological Chemistry.

[345]  Olga Pletnikova,et al.  Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[346]  J. Toretsky,et al.  Recombinant EWS-FLI1 oncoprotein activates transcription. , 2004, Biochemistry.

[347]  Kiowa S. Bower,et al.  Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. , 2002, Neurotoxicology.

[348]  Armin Giese,et al.  Different species of alpha-synuclein oligomers induce calcium influx and seeding. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[349]  Y. Agid,et al.  Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.

[350]  S. Lindquist,et al.  α-Synuclein: membrane interactions and toxicity in Parkinson's disease. , 2010, Annual review of cell and developmental biology.

[351]  J Kim,et al.  Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid. , 1997, Archives of biochemistry and biophysics.

[352]  R. Uitti,et al.  Regional Metal Concentrations in Parkinson's Disease, Other Chronic Neurological Diseases, and Control Brains , 1989, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[353]  K. Chung,et al.  The role of ubiquitin linkages on α‐synuclein induced‐toxicity in a Drosophila model of Parkinson’s disease , 2009, Journal of neurochemistry.

[354]  Natively unfolded human prothymosin alpha adopts partially folded collapsed conformation at acidic pH. , 1999 .

[355]  J. Mallet,et al.  Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. , 2000, Journal of neurochemistry.

[356]  K. Jellinger,et al.  The role of transition metals in the pathogenesis of Parkinson's disease , 1995, Journal of the Neurological Sciences.

[357]  E. Masliah,et al.  Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits α-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions , 2010, The Journal of Neuroscience.

[358]  V. Uversky Alpha-synuclein misfolding and neurodegenerative diseases. , 2008, Current protein & peptide science.

[359]  E. Walter,et al.  Coordination features and affinity of the Cu²+ site in the α-synuclein protein of Parkinson's disease. , 2011, Biochemistry.

[360]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[361]  P. Axelsen,et al.  Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro† , 2003 .

[362]  A. Fink,et al.  Classification of acid denaturation of proteins: intermediates and unfolded states. , 1994, Biochemistry.

[363]  V. Uversky,et al.  Methionine oxidation, alpha-synuclein and Parkinson's disease. , 2005, Biochimica et biophysica acta.

[364]  David R. Brown,et al.  Opus: University of Bath Online Publication Store Alpha-synuclein Is a Cellular Ferrireductase , 2022 .

[365]  D. Eliezer,et al.  NMR mapping of copper binding sites in alpha-synuclein. , 2006, Biochimica et biophysica acta.

[366]  R. Kayed,et al.  Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer* , 2009, Journal of Biological Chemistry.

[367]  Toshiki Nakai,et al.  Prolyl-isomerase Pin1 Accumulates in Lewy Bodies of Parkinson Disease and Facilitates Formation of α-Synuclein Inclusions* , 2006, Journal of Biological Chemistry.

[368]  H. Lashuel,et al.  Towards elucidation of the role of ubiquitination in the pathogenesis of Parkinson's disease with semisynthetic ubiquitinated α-synuclein. , 2011, Angewandte Chemie.

[369]  L. Bubacco,et al.  Dopamine quinones interact with alpha-synuclein to form unstructured adducts. , 2010, Biochemical and biophysical research communications.

[370]  D. Marsh,et al.  Association of α-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR. , 2006 .

[371]  E. Masliah,et al.  alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.

[372]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[373]  E. Masliah,et al.  Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives , 2011, Neuroscience Research.

[374]  M. Brin,et al.  Immunohistochemical localization and distribution of torsinA in normal human and rat brain , 2000, Brain Research.

[375]  Min Zhu,et al.  Lipid binding inhibits alpha-synuclein fibril formation. , 2003, The Journal of biological chemistry.

[376]  N. Voelcker,et al.  Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy. Hypothesis , 2009, Neurotoxicity Research.

[377]  Zsuzsanna Dosztányi,et al.  IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content , 2005, Bioinform..

[378]  S. Doglia,et al.  Compact conformations of α‐synuclein induced by alcohols and copper , 2011, Proteins.

[379]  J. Eibl,et al.  The association of metal ion exposure with alpha-synuclein-like immunoreactivity in the central nervous system of fish, Catostomus commersoni. , 2009, Aquatic toxicology.

[380]  P. Lansbury,et al.  The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. , 2007, Biochemistry.

[381]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[382]  V. Uversky,et al.  Accelerated fibrillation of alpha-synuclein induced by the combined action of macromolecular crowding and factors inducing partial folding. , 2009, Current Alzheimer research.

[383]  P. Lansbury,et al.  Accelerated Oligomerization by Parkinson's Disease Linked α‐Synuclein Mutants , 2000 .

[384]  V. Uversky,et al.  Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. , 2003, The Journal of biological chemistry.

[385]  T. Iwatsubo,et al.  Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. , 2004, Acta neuropathologica.

[386]  V. Uversky,et al.  Nuclear Localization of α-Synuclein and Its Interaction with Histones† , 2003 .

[387]  Jimin Wang,et al.  A regulatable switch mediates self-association in an immunoglobulin fold , 2008, Nature Structural &Molecular Biology.

[388]  E. Morignat,et al.  Transmission of Prion Strains in a Transgenic Mouse Model Overexpressing Human A53T Mutated &agr;-Synuclein , 2011, Journal of neuropathology and experimental neurology.

[389]  D. D. Di Monte,et al.  Effect of 4-Hydroxy-2-nonenal Modification on α-Synuclein Aggregation* , 2007, Journal of Biological Chemistry.

[390]  N. Bonini,et al.  DJ‐1 is present in a large molecular complex in human brain tissue and interacts with α‐synuclein , 2005, Journal of neurochemistry.

[391]  I. Kanazawa,et al.  α‐Synuclein forms a complex with transcription factor Elk‐1 , 2001, Journal of neurochemistry.

[392]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[393]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[394]  H. Dyson,et al.  Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.

[395]  P. Højrup,et al.  Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. , 1997, The Biochemical journal.

[396]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[397]  V. Uversky,et al.  The effect of macromolecular crowding on protein aggregation and amyloid fibril formation , 2004, Journal of molecular recognition : JMR.

[398]  C. Fernández,et al.  Structures behind the amyloid aggregation of alpha-synuclein: an NMR based approach. , 2011 .

[399]  M. Feany,et al.  α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.

[400]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[401]  H De Loof,et al.  Amphipathic helix motif: Classes and properties , 1990, Proteins.

[402]  C. C. Johnson,et al.  Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.

[403]  V. Uversky,et al.  Rifampicin Inhibits α-Synuclein Fibrillation and Disaggregates Fibrils , 2004 .

[404]  K. Kuwajima,et al.  Structural characterization of the molten globule of α‐lactalbumin by solution X‐ray scattering , 1997, Protein science : a publication of the Protein Society.

[405]  C. Griesinger,et al.  Familial Mutants of α-Synuclein with Increased Neurotoxicity Have a Destabilized Conformation* , 2005, Journal of Biological Chemistry.

[406]  S. Chandra,et al.  αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction , 2010, Proceedings of the National Academy of Sciences.

[407]  Makoto Hashimoto,et al.  β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.

[408]  Zeger Debyser,et al.  The aggregation of alpha‐synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[409]  R. Aebersold,et al.  Mass spectrometry in proteomics. , 2001, Chemical reviews.

[410]  J. Dordick,et al.  Polyphenolic Glycosides and Aglycones Utilize Opposing Pathways To Selectively Remodel and Inactivate Toxic Oligomers of Amyloid β , 2011, Chembiochem : a European journal of chemical biology.

[411]  T. Iwatsubo,et al.  Accumulation of phosphorylated α-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy , 2004, Acta Neuropathologica.

[412]  B. Hyman,et al.  Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. , 2001, Journal of neurochemistry.

[413]  B. Hyman,et al.  Small Heat Shock Proteins Protect Against α-Synuclein-Induced Toxicity and Aggregation , 2006 .

[414]  N. Makarava,et al.  Molecular Structure of Amyloid Fibrils Controls the Relationship between Fibrillar Size and Toxicity , 2011, PloS one.

[415]  C. C. Lin,et al.  Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. , 2000, Anticancer research.

[416]  Matthew P Frosch,et al.  The Formation of Highly Soluble Oligomers of α-Synuclein Is Regulated by Fatty Acids and Enhanced in Parkinson's Disease , 2003, Neuron.

[417]  Roberto Cappai,et al.  Modulation of α-Synuclein Aggregation by Dopamine: A Review , 2009, Neurochemical Research.

[418]  P. Fraser,et al.  alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis. , 2004, European journal of biochemistry.

[419]  P. Romero,et al.  Sequence complexity of disordered protein , 2001, Proteins.

[420]  M. Shoji,et al.  A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. , 2009, Parkinsonism & related disorders.

[421]  E. Waxman,et al.  Induction of Intracellular Tau Aggregation Is Promoted by α-Synuclein Seeds and Provides Novel Insights into the Hyperphosphorylation of Tau , 2011, The Journal of Neuroscience.

[422]  Ulrik Gether,et al.  Regulation of dopamine transporter function by protein‐protein interactions: new discoveries and methodological challenges , 2010, Journal of neurochemistry.

[423]  Martin Blackledge,et al.  NMR characterization of long-range order in intrinsically disordered proteins. , 2010, Journal of the American Chemical Society.

[424]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[425]  David Eisenberg,et al.  Structures of segments of α‐synuclein fused to maltose‐binding protein suggest intermediate states during amyloid formation , 2011, Protein science : a publication of the Protein Society.

[426]  A. Bush,et al.  Metals and neuroscience. , 2000, Current opinion in chemical biology.

[427]  Michel Goedert,et al.  Mutation E46K increases phospholipid binding and assembly into filaments of human α‐synuclein , 2004 .

[428]  J. Hahn,et al.  Granular Assembly of α-Synuclein Leading to the Accelerated Amyloid Fibril Formation with Shear Stress , 2009, PloS one.

[429]  M. Stefani,et al.  Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity , 2010, The FEBS journal.

[430]  Harry B. Gray,et al.  α-Synuclein Tertiary Contact Dynamics , 2007 .

[431]  V. Uversky,et al.  Effects of Various Flavonoids on the α-Synuclein Fibrillation Process , 2010, Parkinson's disease.

[432]  P. Lansbury,et al.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.

[433]  C. Tanner,et al.  Environmental Factors in the Etiology of Parkinson's Disease , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[434]  Smita Patel,et al.  Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion* , 2002, The Journal of Biological Chemistry.

[435]  Christopher G. Adda,et al.  Interaction of the Molecular Chaperone αB-Crystallin with α-Synuclein: Effects on Amyloid Fibril Formation and Chaperone Activity , 2004 .

[436]  E. Bergantino,et al.  Conformational Equilibria in Monomeric α-Synuclein at the Single-Molecule Level , 2008, PLoS biology.

[437]  B. Hyman,et al.  CHIP Targets Toxic α-Synuclein Oligomers for Degradation* , 2008, Journal of Biological Chemistry.

[438]  T. Yeates,et al.  Arrangement of subunits and ordering of beta-strands in an amyloid sheet. , 2002, Nature structural biology.

[439]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[440]  J. Trojanowski,et al.  Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.

[441]  A. Singleton,et al.  Association between cardiac denervation and parkinsonism caused by α‐synuclein gene triplication , 2004 .

[442]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[443]  J. Trojanowski,et al.  Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly. , 2008, Biochemistry.

[444]  Isao Nishimura,et al.  Parkin Suppresses Dopaminergic Neuron-Selective Neurotoxicity Induced by Pael-R in Drosophila , 2003, Neuron.

[445]  V. Uversky,et al.  Methionine oxidation, a-synuclein and Parkinson's disease , 2005 .

[446]  D. Lynch,et al.  Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. , 2004, The Journal of biological chemistry.

[447]  Jane R. Allison,et al.  Determination of the free energy landscape of alpha-synuclein using spin label nuclear magnetic resonance measurements. , 2009, Journal of the American Chemical Society.

[448]  Takeshi Nakamura,et al.  Activation of Pyk2/RAFTK induces tyrosine phosphorylation of alpha-synuclein via Src-family kinases. , 2002, FEBS letters.

[449]  Vladimir N Uversky,et al.  Guiding protein aggregation with macromolecular crowding. , 2008, Biochemistry.

[450]  Robert A. Grothe,et al.  Structure of the cross-beta spine of amyloid-like fibrils. , 2005, Nature.

[451]  Y. Sung,et al.  α-Synuclein Interacts with Phospholipase D Isozymes and Inhibits Pervanadate-induced Phospholipase D Activation in Human Embryonic Kidney-293 Cells* , 2002, The Journal of Biological Chemistry.

[452]  F. Marken,et al.  The synucleins are a family of redox-active copper binding proteins. , 2011, Biochemistry.

[453]  N. Hattori,et al.  [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.

[454]  Josephine A. Wright,et al.  Unique copper‐induced oligomers mediate alpha‐synuclein toxicity , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[455]  T. Ulmer,et al.  α-Synuclein Populates Both Elongated and Broken Helix States on Small Unilamellar Vesicles , 2011, The Journal of Biological Chemistry.

[456]  Songsong Cao,et al.  Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model , 2008, Proceedings of the National Academy of Sciences.

[457]  V. Subramaniam,et al.  Membrane Permeabilization by Oligomeric α-Synuclein: In Search of the Mechanism , 2010, PloS one.

[458]  Mark R Cookson,et al.  The biochemistry of Parkinson's disease. , 2005, Annual review of biochemistry.

[459]  Jennifer C. Lee,et al.  Copper(II) Binding to α-Synuclein, the Parkinson’s Protein , 2008, Journal of the American Chemical Society.

[460]  A. Fink,et al.  Mechanism of acid-induced folding of proteins. , 1990, Biochemistry.

[461]  L. Meijer,et al.  Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.

[462]  C. Griesinger,et al.  Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. , 2005, Journal of Biological Chemistry.

[463]  V. Uversky,et al.  Role of Protein−Water Interactions and Electrostatics in α-Synuclein Fibril Formation† , 2004 .

[464]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[465]  David R. Brown Oligomeric alpha‐synuclein and its role in neuronal death , 2010, IUBMB life.

[466]  A. Ashcroft,et al.  Metals accelerate the formation and direct the structure of amyloid fibrils of NAC. , 2005, Journal of inorganic biochemistry.

[467]  H. Lashuel,et al.  The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species. , 2011, Journal of molecular biology.

[468]  M. Feany,et al.  Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo , 2007, The Journal of Neuroscience.

[469]  A. Fulton,et al.  How crowded is the cytoplasm? , 1982, Cell.

[470]  C. Griesinger,et al.  Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[471]  H. Esterbauer,et al.  Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. , 1991, Free radical biology & medicine.

[472]  A. Morris,et al.  Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. , 1998, Biochemistry.

[473]  K. Beyer α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers , 2006, Acta Neuropathologica.

[474]  C. Dobson,et al.  Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. , 2005, Journal of the American Chemical Society.

[475]  C. Griesinger,et al.  Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. , 2006, Journal of the American Chemical Society.

[476]  K. Arima,et al.  Tubulin seeds alpha-synuclein fibril formation. , 2002, The Journal of biological chemistry.

[477]  M. Frasier,et al.  Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. , 2002, The Journal of biological chemistry.

[478]  E. Masliah,et al.  Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model , 2011, The Journal of Neuroscience.

[479]  P. Worley,et al.  Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions , 1999, Nature Genetics.

[480]  G. Chapman,et al.  α-Synuclein overexpression enhances manganese-induced neurotoxicity through the NF-κB-mediated pathway , 2011, Toxicology mechanisms and methods.

[481]  S. Gustincich,et al.  Inhibition of α-Synuclein Fibrillization by Dopamine Is Mediated by Interactions with Five C-Terminal Residues and with E83 in the NAC Region , 2008, PloS one.

[482]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[483]  N. Voelcker,et al.  Calcium(II) selectively induces α‐synuclein annular oligomers via interaction with the C‐terminal domain , 2004, Protein science : a publication of the Protein Society.

[484]  T. Mizutani,et al.  Progressive accumulation of ubiquitin and disappearance of α-synuclein epitope in multiple system atrophy-associated glial cytoplasmic inclusions: triple fluorescence study combined with Gallyas-Braak method , 2005, Acta Neuropathologica.

[485]  Veerle Baekelandt,et al.  The conformation and the aggregation kinetics of α-synuclein depend on the proline residues in its C-terminal region. , 2010, Biochemistry.

[486]  R. Clark,et al.  Posttranslational protein modifications. , 2005, Critical care medicine.

[487]  J. Trojanowski,et al.  Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. , 2002, Science.

[488]  Fabia Febbraro,et al.  Co‐expression of C‐terminal truncated alpha‐synuclein enhances full‐length alpha‐synuclein‐induced pathology , 2010, The European journal of neuroscience.

[489]  Y. Guillaume,et al.  Effect of metals on herbicides–α‐synuclein association: A possible factor in neurodegenerative disease studied by capillary electrophoresis , 2005, Electrophoresis.

[490]  D. Eliezer,et al.  Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.

[491]  Hui-Bie F. Xu,et al.  Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. , 2001, Pharmacological research.

[492]  Gary J. Pielak,et al.  Solvent‐induced collapse of α‐synuclein and acid‐denatured cytochrome c , 2001 .

[493]  P. Lansbury,et al.  Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.

[494]  K. Ono,et al.  β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders , 2008 .

[495]  Carol D. Hicks,et al.  Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent α-Synuclein Oligomer Formation and Rescue α-Synuclein-Induced Toxicity , 2010, Journal of Pharmacology and Experimental Therapeutics.

[496]  C M Dobson,et al.  Designing conditions for in vitro formation of amyloid protofilaments and fibrils. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[497]  V. Uversky,et al.  Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.

[498]  Min Zhu,et al.  Lipid Binding Inhibits α-Synuclein Fibril Formation* , 2003, The Journal of Biological Chemistry.

[499]  Y. Engelborghs,et al.  Raised calcium promotes α-synuclein aggregate formation , 2011, Molecular and Cellular Neuroscience.

[500]  J. Mallet,et al.  Rat α‐Synuclein Interacts with Tat Binding Protein 1, a Component of the 26S Proteasomal Complex , 2000 .

[501]  J. D. Robertson,et al.  Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.

[502]  T. Iwatsubo,et al.  Familial Parkinson Mutant α-Synuclein Causes Dopamine Neuron Dysfunction in Transgenic Caenorhabditis elegans* , 2006, Journal of Biological Chemistry.

[503]  Vladimir N Uversky,et al.  Intrinsically disordered proteins may escape unwanted interactions via functional misfolding. , 2011, Biochimica et biophysica acta.

[504]  M. Farrer,et al.  Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. , 2004, Annals of neurology.

[505]  M. Roy,et al.  Facteurs environnementaux dans l'étiologie de la maladie de Parkinson , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[506]  Bharathi,et al.  Copper- and iron-induced differential fibril formation in α-synuclein: TEM study , 2007, Neuroscience Letters.

[507]  K. Chung,et al.  Human Polycomb protein 2 promotes α-synuclein aggregate formation through covalent SUMOylation , 2011, Brain Research.

[508]  V. Uversky,et al.  Role of individual methionines in the fibrillation of methionine-oxidized α-synuclein , 2004 .

[509]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[510]  E. Montgomery Heavy metals and the etiology of Parkinson's disease and other movement disorders. , 1995, Toxicology.

[511]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[512]  R. Read,et al.  A 2.6 A structure of a serpin polymer and implications for conformational disease. , 1999, Journal of molecular biology.

[513]  P. Lansbury,et al.  Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. , 2000, Biochemistry.